Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension

Canadian Journal of Cardiology

Volumn 23, Issue 5, 2007, Pages 377-382

  Lacourcière, Yves ^a   Poirier, Luc ^a   Lefebvre, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Antihypertensive therapy; Hydrochlorothiazide; Hypertension; Initial combination therapy; Losartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; ANTIHYPERTENSIVE AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34249733752     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70771-7     Document Type: Article

References (29)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-23.
2. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-72. (Erratum in 2003;290:197).
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53. (Errata in 2003;21:2203-4, 2004;22:435).
4. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: Data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens (Greenwich) 2001;3:211-6. (Erratum in 2002;4:76).
5. Mancia G, Bombelli M, Lanzarotti A, et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002;162:582-6.
6. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971;27:335-46.
7. Levy D. The role of systolic blood pressure in determining risk for cardiovascular diseases. J Hypertens Suppl 1999;17:S15-S18.
8. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
9. O'Connor P. Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003;163:2677-8.
10. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996;156:278-85.
11. Lacourcière Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003;16:1036-42.
12. Clement DL, De Buyzere ML, De Bacquer DA, et al; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15.
13. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: Results from the PAMELA study. J Hypertens 1995;13:1377-90.
14. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003;21:1291-8.
15. Myers MG. Blood pressure measurement and the guidelines: A proposed new algorithm for the diagnosis of hypertension. Blood Press Monit 2004;9:283-6.
16. Graettinger WF, Lipson JL, Cheung DG, Weber MA. Validation of portable noninvasive blood pressure monitoring devices: Comparisons with intra-arterial and sphygmomanometer measurements. Am Heart J 1988;116:1155-60.
17. Ioannidis JP, Lau J. Improving safety reporting from randomised trials. Drug Saf 2002;25:77-84.
18. Joffres MR, Hamet P, MacLean DR, L'Italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
19. Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997;30:1410-5.
20. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998;32:983-8.
21. Dahlof B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT BPLA): A multicentre randomised controlled trial. Lancet 2005;366:895-906.
22. Ambrosioni E. Pharmacoeconomics of hypertension management: The place of combination therapy. Pharmacoeconomics 2001;19:337-47.
23. Jamerson KA, Bakris GL, Wun C, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801.
24. After the diagnosis: Adherence and persistence with hypertension therapy. Am J Manag Care 2005;11:S395-9.
25. CHEP Recommendations for the Management of Hypertension 2006. Canadian Hypertension Society. (Version current at March 8, 2007).
26. White WB. Clinical relevance of ambulatory versus clinic blood pressure when evaluating antihypertensive therapy. Blood Press Monit 1996;1:170-3.
27. Waeber B, Rutschmann B, Nussberger J, Brunner HR. Evaluation of antihypertensive therapy: Discrepancies between office and ambulatory recorded blood pressure. J Hypertens 1991;9:S53-6.
28. Lacourcière Y, Carrier M, Toal CB. Efficacy and tolerability of tiapamil in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1989;14:166-70.
29. Lacourcière Y, Leenen F, Rangno R, Spence JD, Lenis JH, Myers MG. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. Can J Cardiol 1994;10:605-10.